soul trial oral semaglutide cardiovascular outcomes 2024 nejm (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine Oral Semaglutide's Impact on Cardiovascular
Pay in 4 interest-free payments of $5.08 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6

01375-3/asset/bffa03de-3da9-472a-a80e-74f8a67c6fdd/main.assets/gr2.jpg)

























